Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2715-2719

  Des Guetz, Gaëtan ^a,b   Mariani, P ^c   Cucherousset, J ^d   Benamoun, M ^d   Lagorce, C ^a,b   Sastre, X ^c   Le Toumelin, P ^a   Uzzan, B ^a   Perret, G Y ^a   Morere, J F ^a   Breau, J L ^a   Fagard, R ^a,b   Schischmanoff, P O ^a,b  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c INSTITUT CURIE   (France)

^d Cardiology Department   (France)

Author keywords

Cancer; Chemotherapy; Colorectal cancer treatment; Combination therapy; FOLFOX; Microsatellite instability

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THORAX RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 34547787797     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR and Buchler MW: Colorectal cancer. Lancet 365: 153-165, 2005.
2. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 49: 8-31, 1999.
3. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO et al: Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53: 5849-5852, 1993.
4. Veigl ML, Kasturi L, Olechnowicz J, Ma A, Lutterbaugh JD, Periyasamy S, Li G-M, Drummond J, Modrich PL, Sedwick WD and Markowitz SD: Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. PNAS 95: 8698-8702, 1998.
5. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN and Srivastava S: A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248-5257, 1998.
6. Umar A, Boland CR, Terdiman JP, Syngal S, Chapelle Adl, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HFA, Hawk ET, Barrett JC, Freedman AN and Srivastava S: Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability. J Natl Cancer Inst 96: 261-268, 2004.
7. Popat S, Hubner R and Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609-618, 2005.
8. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
9. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
10. Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA and Joensuu H: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119: 921-928, 2000.
11. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N and Iacopetta B: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355: 1745-1750, 2000.
12. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M and Gallinger S: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257, 2003.
13. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K and Boland CR: Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126: 394-401, 2004.
14. de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G, Cats A, Morreau H, Gelderblom H and Vasen HF: Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 109: 468-471, 2004.
15. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Pinol V, Xicola RM, Bujanda L, Rene JM, Clofent J, Bessa X, Morillas JD, Nicolas-Perez D, Paya A, Alenda C; for the Gastrointestinal Oncology Group of the Spanish Gastroenterological A: Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55: 848-855, 2006.
16. Tajima A, Hess MT, Cabrera BL, Kolodner RD and Carethers JM: The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 127: 1678-1684, 2004.
17. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
18. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
19. Buhard O, Cattaneo F, Wong YF, Yim SF, Friedman E, Flejou J-F, Duval A and Hamelin R: Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol 24: 241-251, 2006.
20. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ and Boland CR: Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104: 1535-1549, 1993.
21. Gryfe R, Kim H, Hsieh ETK, Aronson MD, Holowaty EJ, Bull SB, Redston M and Gallinger S: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342: 69-77, 2000.
22. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD and Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886, 1996.
23. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, and Chaney SG: The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58: 3579-3585, 1998.
24. Liang J-T, Huang K-CH, Lai H-S, Lee P-H, Cheng Y-M, HsuH-C, Cheng A-L, Hsu C-H, Yeh K-H, Wang S-M, Tang C and Chang K-J: High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 101: 519-525, 2002.
25. Brueckl WM, Moesch C, Brabletz T, Koebnick C, Riedel C, Jung A, Merkel S, Schaber S, Boxberger F, Kirchner T, Hohenberger W, Hahn EG and Wein A: Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 23: 1773-1777, 2003.
26. Ricciardiello L, Ceccarelli C, Angiolini G, Pariali M, Chieco P, Paterini P, Biasco G, Martinelli GN, Roda E and Bazzoli F: High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. Clin Cancer Res 11: 4234-4240, 2005.
27. Baddi L and Benson A III: Adjuvant Therapy in Stage II Colon Cancer: Current Approaches. Oncologist 10: 325-331, 2005.